TABLE 4.
Concomitant maintenance immunosuppression
| Desensitization (n = 10) | No induction (n = 48) | Induction (n = 46) | P | |
|---|---|---|---|---|
| Mycophenolate dose (mg/d) | ||||
| D 7a | 2000 (2000–2000) | 2000 (2000–2000) | 2000 (2000–2000) | 0.01 |
| Mo 1a,b | 2000 (2000–2500) | 2000 (2000–2500) | 2000 (1000–2000) | <0.0001 |
| Mo 3a,b | 2000 (2000–2500) | 2000 (2000–2000) | 1750 (500–2000) | 0.0001 |
| Mo 6a | 2000 (1750–2500) | 2000 (1500–2000) | 1000 (500–2000) | 0.002 |
| Mo 12a | 1000 (1000–2000) | 2000 (1000–2000) | 1000 (1000–2000) | 0.04 |
| Tacrolimus trough concentration (ng/mL) | ||||
| D 7a,c | 4.8 (2.4–7.2) | 8 (6.4–10.4) | 4 (1.8–7) | <0.0001 |
| Mo 1a | 9.3 (6.6–11.4) | 10.7 (8.3–14.1) | 7.9 (5.3–9.9) | 0.0002 |
| Mo 3a | 8.7 (5.9–11.3) | 12 (10–14.3) | 8.4 (6.9–10.8) | 0.0002 |
| Mo 6b | 12.5 (8.8–14.7) | 10 (7.5–13.1) | 8.5 (6.6–10.6) | 0.02 |
| Mo 12a | 7.3 (5.9–11.2) | 9.8 (7.8–13.2) | 8 (5.3–10.3) | 0.01 |
| Corticosteroid dose (mg/d) | ||||
| Cumulative at d 7 | 2103 (1936–2431) | 2049 (1915–2094) | 1994 (1300–2249) | 0.46 |
| D 7a,b | 20 (20–25) | 40 (20–50) | 10 (7.5–20) | <0.0001 |
| Mo 1a,b | 17.5 (13.8–20) | 17.5 (15–20) | 10 (5–10) | <0.0001 |
| Mo 3a | 7.5 (7.5–15) | 10 (7.5–12.5) | 5 (5–10) | 0.0001 |
| Mo 6 | 5 (2.5–5) | 5 (2.5–7.5) | 5 (2.5–5) | 0.11 |
| Mo 12c | 0 (0–0) | 2.5 (0–5) | 0 (0–5) | 0.02 |
Myconolate and corticosteroid doses are standardized to mycophenolate mofetil and prednisone equivalents, respectively. Bold indicates statistically significant difference.
aP < 0.05 for comparison of no-induction cohort to induction cohort.
bP < 0.05 for comparison of desensitization cohort to induction cohort.
cP < 0.05 for comparison of desensitization cohort to no-induction cohort.